Long-term effects of glibenclamide on platelet function in diabetics

In order to investigate whether glibenclamide has antiplatelet effect or not, a prospective study of six months was carried out in 11 NIDD （non-insulin dependent diabetics） whose metabolic disorders could not be controlled by diet alone. The results showed that both platelet adhesion and ADP-induced platelet aggregation were remarkably reduced after 2,4 and 6 months of treatment with glibenclamide as compared with those before treatment （P＜0.0l）. The concentrations of fasting, 1 and 2 hour postprandial blood glucose and HbA₁ were also decreased （P＜0.05）. But the blood insulin levels were slightly increased. The study indicated that, besides hypoglycemic effect, glibenclamide also has an anti-platelet effect in diabetics similar to that of gliclazide.